The incidence of CDKN2A/B deletion in Ph-B-ALL patients (53/126, 42.1%) was significantly higher than that in Ph+B-ALL patients (24/85, 28.2%, P=0.041). This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.